Skip to main content

Collins Helen Louise's Form 4 filing

Enliven Therapeutics, Inc.ELVN · filed May 20, 2026

Accession no.
0001701247-26-000007
Filed
May 20, 2026
Trade date
May 18, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $199.0K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Collins Helen LouiseCIK 0001701247Officer (CHIEF MEDICAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 18, 2026Common StockMOption exerciseAcquired+5,000$2.48+$12,40030,000Direct
May 18, 2026Common StockSSaleDisposed−3,475$39.53F3−$137,366.7526,525Direct
May 18, 2026Common StockSSaleDisposed−1,302$40.25F4−$52,405.525,223Direct
May 18, 2026Common StockSSaleDisposed−223$41.21F5−$9,189.8325,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 18, 2026Common StockMOption exerciseDisposed−5,000$0.00$0126,268Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

This transaction was executed in multiple trades at prices ranging from $38.855 to $39.85. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F4

This transaction was executed in multiple trades at prices ranging from $39.855 to $40.83. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F5

This transaction was executed in multiple trades at prices ranging from $40.8625 to $41.605. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)